With J&J-partnered CAR-T nod in hand, Legend CEO eyes earlier myeloma use, cheaper cell therapy manufacturing

Nearly five years after unveiling the first clinical data for its BCMA-targeted CAR-T therapy, Legend Biotech has transitioned into a commercial company with an FDA approval for Carvykti and Johnso

Related Keywords

,Legend Biotech ,Biotech Ceo ,Carvykti ,Ar T ,Cell Amp Gene Therapy ,Multiple Myeloma ,Drug Launch ,Ohnson Amp Johnson ,Cell Therapy Manufacturing ,Cell Therapy ,Launches ,Sia ,Executives ,Manufacturing ,Marketing ,Fierce Pharma Homepage ,Pharma ,